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A pathological hallmark of asthma is chronic injury and repair, producing dysfunction of the epithelial barrier function. In
this setting, increased oxidative stress, growth factor- and cytokine stimulation, together with extracellular matrix contact
produces transcriptional reprogramming of the epithelial cell. This process results in epithelial-mesenchymal transition
(EMT), a cellular state associated with loss of epithelial polarity, expression of mesenchymal markers, enhanced mobility
and extracellular matrix remodeling. As a result, the cellular biology of the EMT state produces characteristic changes seen
in severe, refractory asthma: myofibroblast expansion, epithelial trans-differentiation and subepithelial fibrosis. EMT also
induces profound changes in epithelial responsiveness that affects innate immune signaling that may have impact on the
adaptive immune response and effectiveness of glucocorticoid therapy in severe asthma. We discuss how this complex
phenotype is beginning to be understood using systems biology-level approaches through perturbations coupled with
high throughput profiling and computational modeling. Understanding the distinct changes induced by EMT at the
systems level may provide translational strategies to reverse the altered signaling and physiology of refractory asthma.
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and children suffer from asthma, representing a major
public health problem worldwide. Over the past two de-
cades, there has been a rise in asthma prevalence, such
that about 8% of the population, more than 25 million
Americans, were affected in 2010 [1]. Asthma is a het-
erogeneous disease whose presentation, clinical course,
and response to therapy is determined by distinct patho-
biological processes [2]. Two prominent asthma patho-
logical processes are chronic inflammation and airway
remodeling; these processes lead to the variable clinical
manifestations characteristic of this syndrome [3]. Of
these pathobiological processes, airway remodeling re-
mains refractory to front-line glucocorticoid suppression
therapy, and is associated with a subtype of asthma* Correspondence: arbrasie@utmb.edu
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unless otherwise stated.known as severe asthma. This subtype is associated with
enhanced morbidity and accounts for disproportionate
health care costs [4].
Recent exciting work has yielded insight into the dynamic
and central role of the epithelium in asthmatic inflamma-
tion and remodeling. In this review, we discuss the cellular
biology of an epithelial transcriptional reprogramming
event known as epithelial-mesenchymal transition (EMT).
Specifically, we examine the current knowledge of how
growth factors and inflammation interface to produce
EMT, of the role of innate immune cells in this process,
and phenotypic modulation by the NF-κB signaling path-
way. Due to the complexity of interacting signals and
consequent global transcriptional reprogramming, systems-
level studies are needed to fully understand critical
pathways affected by EMT. The “systems” concept relies on
global, experimental measurements of the genome, tran-
scriptome, proteome, metabolome, and epigenome in re-
sponse to external perturbation. One advantage of this
approach is that it makes no a priori assumptions about
the mechanisms underlying the response, allowing for the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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biology has already provided new insights about the inter-
action between genes and the environment in asthma
development [6], and environmental control of gene ex-
pression networks [7]. Here, we review findings of systems
level perturbations and computational modeling that have
shed light on how EMT produces dysregulation of the in-
nate immune signaling pathway and we discuss how future
system level studies will lead to potentially new transla-
tional interventions focused on modifying the reprogram-
ming of the asthmatic epithelium.
The epithelium is a central component of airway
inflammation and remodeling
The airway mucosal barrier is produced by a relatively im-
permeable epithelial sheet connected by tight junctions that
restrict fluid loss and limit inhaled particulate access to the
internal milieu. The airway mucosa is a regionally diverse
spectrum of highly differentiated epithelial cell types, each
playing a specialized role in normal pulmonary function
and host defense. For example, flattened simple squamous
type I pneumocytes promote gas exchange, provide a bar-
rier to minimize water loss, and prevent pathogens and
toxins from access to the internal architecture; secretory
goblet cells produce and secrete protective mucins into the
airway lining fluid; ciliated epithelial cells produce protect-
ive epithelial lining fluid and mucociliary escalator for
particulate clearance; and type II pneumocytes secrete sur-
factants responsible for maintaining alveolar patency [8]. In
pseudostratified columnar epithelial tissue, basal epithelial
cells serve a regenerative function, being responsible for
transdifferentiation to repopulate ciliated epithelia, and
Clara and goblet cell populations in response to injury or
senescence [8].
Maintenance of epithelial integrity is critical to normal
cellular signaling, pulmonary homeostasis, and response
to toxicants and allergen exposures. Moreover, this dy-
namic and plastic cell type plays a key role in initiating
innate signaling programs in response to physical, chem-
ical and biological challenge through coordinating cyto-
kine and defensin release, and secreting alarmins and
Th2-differentiating cytokines [9]. Despite intense study
of the Th2 polarization hypothesis [3,10], a body of evi-
dence points to a disruption of the epithelial mucosal
barrier and its chronic regenerative process as playing a
key pathogenic role in diverse forms of asthma.
Asthma is disease driven, in part, by epithelial injury
and repair. Representing the principal cell type between
the environment and internal milieu, the epithelial cell
not only plays a critical role in the activation and coord-
ination of the innate immune response, but also in toler-
ance and control of airway hyper-reactivity. It is well
established that increased epithelial cell fragility with at-
tendant denudation/shedding of epithelial cells and theconsequent disruption of its barrier function enhances
allergic sensitization [8]. CC chemokines CCL2, CCL20
and IL-12p40 produced by stimulated epithelial cells
activate tissue-resident dendritic cells to produce Th2
polarization characteristic of asthma [3,11]. The loss of ap-
ical polarity, increased Goblet cell number (metaplasia) and
expansion of the myofibroblast population are characteris-
tic histological features of severe asthma. In animal studies,
cellular lineage experiments have shown that epithelial cells
contribute significantly to the myofibroblast population
[12]. These data suggest that the epithelium plays signifi-
cant pathogenic roles in the genesis and maintenance of
reactive airway disease [9].
Inducible epithelial phenotypes: Epithelial-
Mesenchymal Transition (EMT) and
transdifferentiation
Under normal conditions, the airway epithelial cells signal
to an attenuated sheath of subepithelial mesenchymal cells,
forming an epithelial-mesenchymal unit (EMU). Integrity
of the EMU depends on growth factors secreted from epi-
thelial cells; growth factor secretion is rapidly increased in
response to epithelial injury to promote regeneration of this
critical mucosal surface [13]. Injury, subsequent inflamma-
tion and the loss of epithelial basement membrane integrity
also promote epithelial cell activation by extracellular
matrix-associated factors. These resident factors include
the growth factors epidermal growth factor (EGF), fibro-
blast growth factor (FGF), and TGFβ, whose actions are
modified by innate immune cytokines (such as IL-6, IL-1β,
MCP-1 and RANTES) produced by epithelial and tissue
resident leukocytes [9,14]. These factors transform special-
ized epithelial cells to become motile, fibroblast-like cells;
this process is referred to as type II EMT [15], a response
central to repair after tissue injury. In addition to TGFβ,
hypoxia is a strong inducer of EMT in kidney and lung epi-
thelia [16,17]. Reactive oxygen species (ROS) produced in
hypoxic settings are as potent inducer of EMT as that of
TGFβ [16,18]. EMT can also be initiated by other growth
factors such as FGF-2, EGF, and connective tissue growth
factor (CTGF) [19].
Because TGFβ is the most potent and most well de-
scribed inducer of EMT, we will discuss its role in modify-
ing the airway epithelia in detail. In the airway mucosa,
TGFβ induced type II EMT leads to disruption of mucosal
barrier function by inducing the loss of apical polarity, re-
duced epithelial cadherin (ECad) and disruption of epithe-
lial adherens junctions (Figure 1; [9,10]). In addition, type II
EMT enables transformed epithelial cells to express α-SMA
stress fibers and intermediate filament vimentin, to produce
ECM through secretion of collagen and fibronectin, and to
increase expression of matrix metalloproteinases (MMPs)
to promote airway remodeling. Finally, EMT also produces
complex alterations in the innate immune response [20], a
mucosal permeability














Figure 1 Schematic view of EMT in the airway. Shown is a segment of airway epithelium and homeostatic properties affected by type
II EMT. The induction of type II EMT is modulated by growth factors released from the ECM and tissue resident leukocytes (eosinophils)
and results in loss of adherens junctions (aj), loss of apical-basal polarity and disruption of mucosal barrier function, enhanced ECM
deposition and dysregulated innate signaling. Also, there is suppression of innate immunity in some asthmatics but the link between
EMT and suppression of innate immunity needs to be explored further. TGFβ, transforming growth factor beta; FGF, fibroblast growth
factor; EGF, epithelial growth factor.
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be a protective mechanism for tissue repair, excessive and
prolonged EMT processes can lead to fibrosis and organ
damage as observed in lung [12], liver [21] and kidney
fibrosis [22].
Other injury-induced epithelial differentiation paradigms
may represent “formes frustes” of EMT. Chronic stimula-
tion with growth factors EGF and amphiregulin, modified
by Th2-derived IL-4 and IL-13 cytokines are thought to be
responsible for expansion of the mucus-producing Goblet
cell population [9]. Goblet cell hyperplasia is the product of
trans-differentiation of ciliated and Clara cells. Goblet cells
are responsible for expression of MUC5A and MUC5B,
glycoconjugates that alter the hydro-elastic properties of
mucus in asthma. In this way, stressed epithelial cells within
the inflammatory milieu of airways disease are induced to
undergo distinct phenotypic switches in ways that funda-
mentally alter the normal function of the epithelium and
play an important role in airway remodeling in asthma.EMT in asthma
In asthmatic patients, the airway is fragile with de-
creased cell-to-cell adhesion, a process due, in part, to
reduced ECad expression [23]. Immunoreactivity for
TGFβ and its activated intracellular pathway protein,
phospho-Smad2 (p-Smad2), are increased in mucosal bi-
opsies suggesting the presence of active TGFβ signaling
in asthmatic epithelium [24-26]. These and other lines
of evidence suggest that EMT plays an important role in
pathogenesis of subtypes of asthma [14,27]. Isolated hu-
man primary airway epithelial cells from asthmatics lose
zona occludin-1 (ZO-1) expression at lower TGFβ con-
centrations than that required for normal epithelial cells
[28]. In studies of pseudostratified columnar epithelial
cells cultured in an air-liquid interface, TGFβ-induced
EMT occurs in the basal cell layer, a stem-cell like popu-
lation involved in trans-differentiation of numerous epi-
thelial cell types [28]. Evidence of detrimental effects of
TGFβ in the lung comes from mouse models where
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the airway epithelium using adenovirus vectors induces
airway collagen mRNA and protein deposition [29]. Conse-
quently, neutralization of TGFβ reduces pulmonary fibrosis,
collagen deposition and smooth muscle proliferation [30].
Accumulation of TGFβ in the bronchoalveolar lavage fluid
of chronic asthma patients as well as in sensitized experi-
mental animals challenged with OVA suggests a critical role
of TGFβ in airway remodeling and lung EMT [28,31,32].
These data suggest that there is dysregulated TGFβ signal-
ing in asthmatics and allergic airways which leads to disrup-
tion of the epithelial barrier function, mucosal remodeling
and fibrosis.
Signaling pathways producing EMT
The molecular signaling of how TGFβ1 initiates EMT has
been studied in some detail (Figure 2). Free TGFβ binds to
TGFβ receptor type II (TGFβRII), a transmembrane serine,
threonine kinase that recruits and phosphorylates TGFβRI.


































Figure 2 Pathways activated by TGFβ to induce EMT. An idealilzed epi
non-canonical TGFβ intracellular signaling pathways. The TGFβ signaling is
(ZEB) and Twist (Twst) that induce transcriptional reprogramming and chro
pathways result in repression of ECad (CADH1) and upregulation of fibrone
interconnections with the TNF-NFκB inflammatory response are diagrammethen recruits Smads 2/3, cytoplasmic transcription factors
that are, in turn, phosphorylated by TGFβRI on serine resi-
dues. Phosphorylated Smad2/3 binds to Smad4 and the
complex then translocates to the nucleus. The activated
Smad 2/3/4 trimer binds to Smad-binding elements in the
regulatory regions of junB and c-Jun, and modulates
transcription with other coactivators including the cAMP-
response element binding protein (CBP)/p300 histone ace-
tyltransferases [33].
TGFβ1 binding to its receptors also stimulates nonca-
nonical signaling pathways including PI3K/Akt, Ras
small GTPases, Wnt/β-catenin, ERK, p38, and JNK. Al-
though Smad and non-Smad pathways are both activated
by TGFβ, it is difficult to distinctly separate the actions
of Smads from non-Smad proteins since there is signifi-
cant cross-talk between the signaling arms with Smads
regulating some non-canonical pathways and vice versa
[34]. In most instances, Smad-dependant signaling is
dominant in mediating EMT but non-Smad proteins are


















thelial cell before and after EMT showing the canonical (smad) and
upstream of the master transcriptional regulators, snail (SNAI1/2), zebra
matin remodeling through histone modification. Stimulation of TGFβ
ctin (FIB), collagen 1 (Col1) and α-SMA in the epithelial cell. Known
d.
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tion, but production of fibronectin is dependent on
ERK1/2 and JNK [35]. Mechanistically, it has been dem-
onstrated in a fibrosarcoma cell line that TGFβ1 acti-
vates MAPK4-JNK1, leading to dimerization of the c-Jun
and ATF2 transcription factor to initiate transcription of
the fibronectin gene [36]. Recent findings in Non-Small
Cell Lung Cancer cell lines indicate that TGFβ1 induced
phospho-Erk1/2 mediates a decrease in ECad and an in-
crease in fibronectin expression [37]. Inhibition of JNK,
p38 and Akt activities without affecting Smad phosphor-
ylation blocks TGFβ1 induced α-SMA, SNAI1 and colla-
gen I in primary alveolar epithelial cells [38]. Another
important non-Smad pathway linking epithelial tight
junctions to cytoskeletal changes is the β-catenin path-
way. TGFβ1 stimulation causes an increase in α-SMA
via SMAD3-β-catenin-CBP interaction on the α-SMA
promoter [39]. β-catenin is part of the complex that me-
diates binding of ECad to the actin cytoskeleton. There-
fore, downregulation of ECad allows for more availability
of β-catenin to bind to Smads, thus providing a unifying
mechanism by which epithelial cells lose their apical
polarity and undergo cytoskeleton rearrangement to
become motile myofibroblasts.
Currently, it is thought that three families of transcrip-
tion factors function as key regulators of EMT: snail
(SNAI)1/2, zebra (ZEB)1/2, and Twist 1/2 families [40].
In the canonical pathway, TGFβ-stimulation upregulates
SNAI expression via Smad3/4. A SNAI1-smad3/4 com-
plex then binds to regulatory promoter regions of ECad
and ZO-1, leading to their repression [41]. Smad signal-
ing also increases ZEB1/2, a transcriptional repressor of
the miR-200 family of micro RNAs. The mir-200 family
represses translation of ZEB1/2, TGFβRI and Smad2. In
this manner, miR-200 repression by ZEB1/2 promotes
EMT by increasing TGBR mediated signaling [42]. In
addition, these transcription factors control the expres-
sion of matrix metalloproteinases (MMPs) and ECM
proteins such as collagens [40].
Modulators of the EMT program
Several studies suggest that the ability of TGFβ to induce
EMT is modulated by innate cytokine stimulation, morpho-
gen signaling, allergen exposure and through ECM interac-
tions. Studies of transformed alveolar basal epithelial cells
show that TGFβ-induced EMT is accelerated by the pres-
ence of members of the proinflammatory TNF/ IL-1 super-
family of cytokines [43-45]. TNF/ IL-1 through intracellular
adapters trigger the innate immune response activating
downstream Ras GTPase, p38 MAPK and JNK, key com-
ponents of the noncanonical TGFβ signaling pathway
(Figure 2). Additionally, IL-1/TNF controls NF-κB, a
master regulator of airway inflammation [46] that regulates
a ~4,000 member gene network mediating anti-apoptosis,inflammation, and adaptive immunity [47,48]. NF-κB has
been identified as a key regulator of the core EMT pro-
gram, deserving specific mention. In studies of cancer-
associated (so-called type III) EMT, NF-κB is required for
growth factor-induced SNAI expression by directly indu-
cing expression of the SNAI gene [49]. Similarly, NF-κB
upregulates the ZEB1/2 transcription factors that mediate
transcriptional silencing of the ECad gene and upregulation
of the vimentin (VIM) promoter. In a similar manner, TNF-
inducible Twist1 expression is mediated by NF-κB [50],
explaining, in part, how the IL-1/TNF superfamily of cyto-
kines mediates EMT. Other exciting studies have shown that
activated NF-κB may also directly bind and stabilize SNAI,
promoting its pro-EMT activity [51]. In addition to the
well described TNF/IL-1 ligands, the superfamily member
LIGHT (TNFSF14) is a T cell coactivator that mediates
chronic airway inflammation and is associated with asthma
disease severity [52]. LIGHT modulates TGF-β1-induced
EMT by suppressing E-cadherin and enhancing vimentin
expression [53]. Interestingly, LIGHT can also induce EMT
independently from that of the TGF-β1 pathway through
activation of Erk1/2 signaling [53]. Together these data
indicate that TNF/IL-1 superfamily through NF-κB signaling
plays a central, upstream coordinating role in EMT through
both transcriptional and post-transcriptional actions.
The actions of TGFβ on EMT are further controlled
by the Notch pathway, a highly conserved morphen con-
trol pathway involved in epithelial intercellular commu-
nication and cell fate specification. In cultured rat
alveolar epithelial cells, Notch activation increases the
expression of α-SMA, collagen I and vimentin and
decreases expression of epithelial markers. Notch pro-
motes EMT in airway epithelia by increasing expression
of TGFβ ligands and inducing myofibroblast differenti-
ation of alveolar epithelial cells via the TGFβ -Smad3
pathway [54].
Vascular endothelial growth factor (VEGF), matrix
metalloproteinase-9 (MMP-9), and Th2-type cytokines (IL-
5, −13, −4 and −9) produced by adaptive immune cells in
the lung have also been observed to modulate EMT
[55-58]. Moreover, the pro-inflammatory IL-17A cytokine
directly regulates EMT and collagen synthesis in a TGFβ1-
dependent process [59]. Neutralizing IL-17A promotes
autophagy and attenuates pulmonary fibrosis [59]. This
latter mechanism may be important in the pathogenesis
of neutrophilic asthma, a subtype of severe steroid refrac-
tory asthma characterized by Th17-mediated neutrophilic
inflammation.
The ECM is an interlocking mesh of collagens, elastic
fibers and glycoproteins that plays a critical role in
epithelial polarization, proliferation and signaling [60].
Dynamic remodeling of the ECM in response to injury
releases local depots of TGF to stimulate proliferation,
repair and EMT. In addition, the composition and
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epithelial cell signaling and function. Exposure of pri-
mary alveolar cells to fibronectin or fibrin led to robust
EMT, a phenomenon dependent on αVβ6 integrin [12].
In a follow-up study, deletion of α3 integrin in lung epi-
thelium prevented mice from developing fibrosis and led
to a decrease in myofibroblast population and collagen I
expression after bleomycin injury [61]. These findings
strongly suggest that EMT is regulated by contextual
factors such as cytokines and ECM interactions through
integrin signaling.
Finally, extrinsic environmental stimuli can induce
EMT. One prominent example is the house dust mite
aero-allergen; exposure to house dust mite potentiates
TGFβ-induced EMT of airway epithelial cells by stimu-
lating myosin light chain phosphorylation and actin
reorganization and enhanced β-catenin signaling [62].
This is mechanistically important because the β-catenin-
Wnt pathway regulates expression of SNAI2/Slug a tran-
scriptional repressor of ECad. Infection with Respiratory
Syncytial Virus (RSV), a paramyxovirus widely consid-
ered a risk factor for development of allergic asthma
later in life, is also characterized by increased expression
of SNAI1 and TGFβ1, master regulators of EMT [63].
Effector cells of airway remodelling and EMT;
contribution to potential endotypes of asthma
Airway remodeling, in addition to inflammation, abnor-
mal neurogenic and contractile response, has recently
been appreciated as one of the contributors to the symp-
toms, abnormal physiology and natural history of asthma
and therefore is likely to generate manifestation of the
disorder as phenotype. This novel concept led to a series
of studies delineating cellular and molecular mecha-
nisms of airway remodeling and clinical trials aiming to
identify subpopulations of asthmatics with similar dis-
ease mechanism (endotype) [64,65]. Airway remodeling
is a collective term for structural alterations of airways
encompassing the subepithelial fibrosis, myofibroblast
hyperplasia and smooth muscle hypertrophy. The role of
EMT in the development of subepthelial fibrosis, has
been considered [28,66] upon observation of elevated
TGFβ1 production by eosinophils and fibroblasts in pa-
tients with severe and moderate asthma [67,68]. Studies
of allergen-induced airway remodeling in transgenic
mice suggested an important role of TGFβ1, VEGF, Th2
cytokines (IL-5, IL-4, IL-13), and epithelial derived NF-
κB regulated chemokines in airway remodeling, while
eosinophils have received attention as cells contributing
to thickening of reticular basal membrane [14]. Mechan-
istically, eosinophils are the source of potent cytotoxic
mediators, such as leukotrienes, metalloproteinases, and
growth factors, including TGFβ1 [69]. In patients with
severe asthma, eosinophils constitute the majority ofTGFβ1 producing cells as bronchial biopsies showed
that 65% of TGFβ1 mRNA-positive cells are eosinophils
and 75% of lung eosinophils were positive for TGFβ1
mRNA [70]. Animal studies of airway inflammation
using interleukin-5 and eotaxin-transgenic models indi-
cate that goblet cell hyperplasia, epithelial hypertrophy,
and focal collagen deposition are eosinophil-dependent
[71,72]. Complementing these observations, ΔdblGATA
eosinophil-deficient and IL-5-deficient mice showed
significant reduction in subepithelial collagen deposition
and smooth muscle proliferation upon single challenge
or chronic exposure to allergen [56,73]. Furthermore,
allergen challenge experiments in IL-5-deficient mouse
showed decreased numbers of TGFβ1 -positive cells in
the peribronchial region and reduced expression of
TGFβ1 in the whole lung [57]. The role of eosinophils in
mediating EMT was directly shown in experiments
where intratracheal instillation of bone marrow-derived
eosinophils into mouse airways resulted in a marked de-
position of type I collagen and significant fibrosis [74].
These changes were accompanied by decreased ECad
and increased α-SMA expression 21 d after eosinophil
instillation. These findings complemented an earlier
study employing anti-IL-5 antibody in patients with se-
vere eosinophilic asthma refractory to corticosteroids
that demonstrated that a reduction in eosinophils was
associated with decreased basement membrane depos-
ition of tenascin, lumican and procollagen type III [75].
However, there are several observations suggesting
that airway remodeling in asthma may occur without
significant involvement of eosinophils [76] or even in
the absence of inflammation. For example, repeated
methacholine-induced bronchoconstriction in mild
atopic asthmatics resulted in airway remodeling com-
parable to that of induced by allergen challenge [77]. This
remodeling was accompanied by increased expression of
TGFβ1 in the bronchial epithelium without airway eosino-
philia suggesting heterogeneous upstream mechanisms me-
diate airway remodeling. Besides eosinophils, macrophages
of alternative phenotype (known as the “M2 type”) were
shown to participate in lung fibrotic processes in experi-
mental models of nematode infection in IL-4R deficient
mice [78,79]. Macrophage polarization toward the M2
phenotype is characterized by increased expression and
secretion of TGFβ1 and can be achieved by stimulation of
macrophages with IL-4, IL-13 [80] and glucocorticoids [81].
Although the ability of M2 macrophages to produce TGFβ1
upon stimulation of cytokines overexpressed in asthmatic
airways implied their involvement in fibrotic and re-
modeling processes in asthma, recent observations
have, however, shown overlapping of M1/M2 pheno-
types and conversion of one phenotype to another de-
pending upon the inflammatory response [82]. Similarly
to macrophages, bronchial smooth muscle cells and
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remodeling after observation of enhanced secretion of
TGFβ1 in response to neutrophil-derived elastase [83,84].
Since neutrophils infiltrate airways in severe and chronic
asthma, their ability to mediate production of TGFβ1
may affect airway remodeling seen in this group of
patients [85].
The correlation of airway remodeling with features of
EMT, expression of TGFβ1, severity of disease, resistance
to glucocorticoid therapy and airway eosinophilia or neu-
trophilia can be used to define distinct molecular pheno-
types of asthma and to some degree asthma endotype. The
asthma “phenotype” is the result of a complex constellation
of pathophysiological processes, whereas an “endotype”
represents a subtype of disease defined functionally and
pathologically by a singular molecular mechanism translat-
ing into a treatment response [86,87]. Although no single
endotype of asthma has yet been fully characterized, several
potential endotypes were proposed based on clinical char-
acteristics, biomarkers, histology and treatment response.
In this regard, the phenotype of steroid-refractory asthma
may include the potential endotype of steroid-insensitive
eosinophilic asthma, a relatively rare form of asthma with
airway eosinophilia, histological features of airway remodel-
ing, glucocorticoid resistance and sensitivity to anti-IL-5
treatment [86]. This endotype mechanistically resembles
IL-5 transgenic or IL-5 deficient mouse models [75].
Future research exploring the role of EMT in airway
remodeling may delineate that EMT may play a role
common to several endotypes. For example, EMT
may contribute to steroid insensitivity as suggested by
decreased induction of anti-inflammatory genes by glu-
cocorticoids in TGFβ1-EMT transformed cells A549
cells [88]. In neutrophilic asthma, another subtype of
severe steroid refractory asthma characterized by Th17-
mediated neutrophilic inflammation and the absence
of airway eosinophilia, airway remodeling may result
from EMT induced by TGFβ1 released from elastase-
stimulated bronchial smooth muscle cells and/or den-
dritic cells [85]. Furthermore, even the endotype of
Th2-high, early-onset asthma with high eosinophilia and
good response to steroid treatment exhibits some fea-
tures of airway remodeling [89] as shown by thickening
of reticular basement membrane by median age of
29 months in preschoolers with recurrent wheezing [90].
Although not yet defined, this endotype, driven by IL-4
and IL-13, may feature a role of TGFβ1 released from
M2 polarized macrophages or from macrophages
activated during phagocytosis of apoptotic eosinophils.
Similarly, the severe, late-onset eosinophilic asthma
endotype, representing 20% of the severe asthma popula-
tion [91], also shows features of TGFβ1 mediated EMT
and airway remodeling in spite of good response to
systemic corticosteroid therapy.In conclusion, future studies aiming at defining asthma
endotypes should consider identification of mechanisms
and respective biomarkers of TGFβ1 mediated EMT.
Search for specific endotype biomarkers must focus on
homogenous group of patients according to underlying
disease mechanisms described by histological features
(e.g. eosinophilia, M2 polarized macrophages), cytokine
signatures (e.g. TGFβ1, IL4, IL-5) and responsiveness to
anti-cytokine and glucocorticoid therapy. Systemic stud-
ies need to be directed at the cellular, molecular, and
genetic factors that are responsible for determining why
only some asthmatics develop significant remodeling.
The information gathered from these studies will impact
strategies employed to combat this increasingly complex
and heterogeneous disorder.
Effects of EMT on epithelial innate signaling
responses
In addition to affecting glucocorticoid response dis-
cussed above, changes in the phenotype of epithelial
cells in asthma may determine effects on innate signal-
ing responses [20]. Our earlier systems-level study ob-
served that EMT had dramatic effects on the induction
of the innate NF-κB pathway by producing an exagger-
ated inflammatory response and by reducing the coup-
ling interval between the rapid canonical response and
the slower noncanonical pathway. Previous work has
shown that type III EMT is associated with epigenetic
modifications on specific genetic loci, including induc-
tion of the euchromatin mark H3-lys4 trimethylation, or
the transcriptional mark H3K36 trimethylation [20,92].
Our studies in primary human airway cells indicated that
enhanced responsiveness of the NF-κB pathway is medi-
ated by accumulation of H3K4 trimethylation marks in
NF-κB-dependent genes working in concert with tran-
scriptional elongation [20]. Transcriptional elongation is
a characteristic gene control mechanism of innate re-
sponse genes mediated by the cyclin-dependent kinase
(CDK9). Our findings indicate that EMT induces genetic
reprogramming of innate response genes through reposi-
tioning of activated histone transcriptional marks and
through modification of CDK activity (schematically dia-
grammed in Figure 3). As a result, the dynamic inflam-
matory response of the epithelial cell is fundamentally
changed by the EMT state. However, the mechanism by
which specific loci are targeted for chromatin modifica-
tions is still unclear.
Further systems level studies will help to understand the
complexity of the epigenetic reprogramming with the indu-
cible phenotype produced by EMT. These approaches
include mathematical modeling of signaling pathways to
infer how EMT influences dynamic responses, systematic
phosphoprotein profiling in response to cellular stimulation


























Figure 3 Consequences of EMT on innate signaling. The innate NFkB pathway is composed of the rapidly responding (canonical)- and the
slower responding (noncanonical) pathways. The canonical pathway controls the inflammatory response, and is coupled to the noncanonical
pathway through a feed-forward pathway by the synthesis of TRAF1 and NFκB2, two rate limiting factors in noncanonical pathway activation.
Through epigenetic reprogramming and enhanced transcriptional elongation through the cyclin dependent kinase (CDK), the rate-limiting
TRAF1/NFκB2 translation is reduced, resulting in enhanced pathway activation in EMT.
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sites at a genome-wide level. Application of this latter
methodology has identified motifs that likely regulate dy-
namics of Polycomb-mediated histone modifications during
murine stem cell differentiation [93]. Furthermore, whole
genome studies have shown H3K36me3 is a specific epi-
genetic signature that modulates selection of exon-intron
junctions, thereby allowing expression of mRNA splice
variants characteristic of EMT [94,95].
Effects of EMT on innate/adaptive immune cell
signaling
Severe asthma is associated with defects in innate immunity
[4], including increased susceptibility to rhinovirus (RV) in-
fections, leading to increased lower respiratory tract inflam-
mation and hyper-reactivity. EMT-induced remodeling of
the epithelial basement membrane promotes sensitization
to inhaled allergen by causing persistent dendritic cell (DC)activation and migration [96]. Two studies have shown that
sentinel respiratory cells replicate rhinovirus more effi-
ciently and show deficient induction of type I/III IFNs,
IFNs-β and -λ, with impaired ability to induce apoptosis
[97,98]. This defect in type III IFN production was highly
correlated with severity of RV-induced asthma exacerbation
and virus load in experimentally infected human volun-
teers, suggesting that asthmatics have an acquired defect in
type III IFN production in sentinel cells of the airway. The
contributions of EMT in modulating the innate and adap-
tive immune responses, such as IFN-γ and TGF-β produc-
tion, require further exploration.
Although the effect of type II EMT on innate and
adaptive immunity in the airway is incompletely delin-
eated, the understanding of type III EMT on adaptive
immunity has been extensively investigated. Epigenetic
modifications induced in type III EMT suppress tran-
scription of the NK cell activating receptor, NKG2D
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by localized cell-surface expression of NKG2D ligands
[101]. SNAI1, the EMT master regulator, promotes im-
munosuppression by inducing differentiation of imma-
ture DCs into regulatory DCs with low MHC class II
expression and associated costimulatory molecules and
prevents NKG2D expression in NK cells [102], thus sup-
pressing the innate immune response. Tumor cells also
acquire resistance to lysis by antigen-specific CTLs fol-
lowing EMT by induction of autophagy through Beclin 1
[103]. Even though there is overlap between type II and
type III EMT signaling and EMT’s effect on immunity,
more work is required to determine which features of
EMT are shared by the two EMT programs and to
understand the role of EMT in modifying the innate
immune response, autophagy and immunoediting in
asthma.
Systems level studies of the EMT phenotype
Discussed above, the complex events produced by tran-
scriptional reprogramming and global epigenetic rearrange-
ment by EMT fundamentally change the inducible
phenotype of the airway epithelial cell. To better under-
stand the various asthma phenotypes, systems level studies
of EMT are needed. Systems biology is an iterative process
that involves the application of high throughput measure-
ments to cellular perturbations. These data are used to
develop predictive models that drive subsequent rounds of
experimentation, perturbations, and predictive model
refinement (Figure 4). Application of the systems biology
approach can fundamentally contribute in-depth under-
standing of how signaling pathways and their interactions
may be dysregulated by EMT (Figure 4).Figure 4 Systems approaches to EMT. Systems biology is an iterative pr
leading to refinement of predictive mathematical models, developing newA classic example of implemented framework of sys-
tems biology was the comprehensive study of the com-
piled gene expression data from five publicly available
mouse microarray datasets and 4,305 gene annotation
sets to provide the functional knowledge base [104]. A
Module Networks analysis was used to identify co-
regulated gene modules, inferring four distinct responses
to treatment, including early response, general induc-
tion, repression, and IL-13–dependent response to the
treatment. Each module consists of potential set of genes
in a pathway interaction map responsible for the corre-
sponding effect. Among the novel observations include
heterogeneity in the gene expression of genetically
identical animals, a transcriptionally distinct module of
known and potentially novel asthma genes.
High-throughput proteomics and metabolomics have
helped to classify asthmatic patients by many proteins
found in the airways, which can be used clinically as
useful biomarkers [105,106]. Saha et al. compiled the
asthma biomarkers from genomics, proteomics, epigen-
etics and few experimentally validated datasets, and
derived significant enrichment of pathways, including
adipokine and ROS pathways [107]. Similarly, gene pro-
filing studies on cancer-related type III EMT have shown
that TGFβ induces global changes in mRNA expression,
mRNA splicing [108] and microRNA expression [109].
Parallel proteomics studies have demonstrated that type
III EMT induces growth factor independence pathways
downstream of IL-6 signaling [110], which has led to a
better understanding of cellular and signaling processes
involved in cancer metastases [111,112].
A recent study focused on the consequences of EMT
to pro-survival signaling using a correlation analysis ofocess of high throughput measurement in response to perturbations,
mechanisms and subsequent rounds of testing.
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RNA transcript abundance [110]. These measurements
were used to quantitate the differences in signaling
dynamics between three different states of EMT: pre- or
potential-EMT state, a reversible ‘metastable’ EMT state
and an ‘epigenetically-fixed’ EMT state. The cross-
correlation strategy showed differential abundance
amongst multiple EMT models (218 proteins, 146 phos-
phoproteins and nearly 1200 RNA transcripts). A func-
tional clustering analysis further identified significantly
enriched yet differentially regulated networks between
epithelial and mesenchymal states. A number of marked
changes in cell-cell junctional proteins involved in cell
polarity, desmosomal junctions and adhesion to base-
ment membrane were observed with EMT. There were
also substantial changes in autocrine networks (EGFR,
Met and IGIFR family) and metabolic networks (redox-
stress, glycolytic and oxidative pathways) with EMT. A
gain of six networks with EMT including IL-11 and IL-6
mediated gp130-JAK activation was also measured. A set
of EMT transcription nodes were also identified suggest-
ing that observed differences in phenotypes could be
correlated with specific transcription components, one
being NF-κB2/RelA. Carefully designed systems ap-
proach revealed significant differences between epithelial
and mesenchymal signaling states, thus providing new
avenues for drug discovery research for modulating type
III EMT. Interestingly, a genome wide profiling of chro-
matin signatures in human genome showed that active
promoters are marked by histone-3 lysine-trimethylation
whereas enhancers are marked by monomethylation
[113]. Similar distinct signatures may be present and
may be a predictive tool between “metastable” and “epi-
genetically-fixed” EMT states.
By contrast, fewer systems level studies have been
applied to understand type II EMT. Although there are
likely to be some important commonalities between
types II and -III EMT, type II EMT is qualitatively differ-
ent process because EMT of primary epithelial cells is
not produced in the milieu of p53 mutation, activation
of Wnt/β catenin or constitutive activation of NFκB
pathways, pathways that modulate EMT. To better
understand the effects of type II EMT on innate signal-
ing, we have applied systems level studies of type II
EMT using innate perturbations. Time-course perturb-
ation experiments were used to develop parameters of
mathematical models of the innate pathway [20]. Com-
putational simulations predicted that a cap-independent
translational mechanism of the rate-limiting TRAF-1-
and NF-κB2 proteins was responsible for reducing the
noncanonical pathway coupling interval observed ex-
perimentally. These predictions were confirmed experi-
mentally using inhibitors of cap-independent translation
[20]. In this way, application of systems modeling andperturbations provided novel insight into how the
complex transcriptional reprogramming events of EMT
influence dynamic response of the innate pathway.
Further applications of systems approaches will pro-
vide comprehensive understanding of this complex
phenotype through deterministic modeling and multidi-
mensional genomic and proteomic profiling (Figure 4).
This kind of integrative approach can potentially provide
information about cytokines and growth factors that
interact to promote EMT through changes in chromatin
remodeling (histone modifications, methylation), post-
translational modifications (phosphoproteomics) and
pathway crosstalk. Mathematical modeling of protein in-
teractions discovered from different “omics” represent-
ing various pathways in asthma have been used to
predict possible drug target genes [114]. Upon integrat-
ing data from various platforms and multiscale informa-
tion from molecular to organ level, the usefulness of
mathematical modeling has previously been demon-
strated [115,116]. These studies provide new insights
and predictions about treatment, response behavior and
time, new drug formulations and optimization in a co-
herent manner. In addition to understanding the patho-
physiology of asthma, the systems biology approach will
also allow the process of developing new therapies,
which will be more specific and cost-effective and yet,
customized to patients phenotypes, thus expediting the
clinical trials. An excellent example is the development
of a novel approach for diagnosis of chronic obstructive
pulmonary disease by coupling systems biology with
label-free high-throughput detection [117]. Similar to
the integrated proteomic studies of type III EMT dis-
cussed above, it would be interesting to see whether sys-
tems approaches can identify transcription nodes that
govern type II EMT. Application of predictive biology
will inform strategies for how to reprogram EMT state
in complex organisms. Increasing our understanding of
the role of EMT in asthma by systems biology will help
us find and test personalized treatment options based
upon particular characteristics of the disease phenotype.
Translational implications
EMT is a complex, dynamic epigenetic reprogramming
event that plays a homeostatic role in airway response to in-
jury. Left unchecked, EMT contributes to pathophysiology
of severe asthma. Understanding how to reverse EMT has
significant translational implications. For example, EMT af-
fects the response to glucocorticoids and inflammatory cy-
tokines in epithelial progenitor cells, an effect that probably
plays a significant pathophysiological component in a num-
ber of asthma phenotypes. It is possible that reversal of the
EMT phenotype may promote allergen tolerance, enable
anti-inflammatory treatment response, reduce viral-induced
exacerbations, and reverse of sub-epithelial fibrosis in
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are only beginning to be defined, and could involve target-
ing modulatory TGFβ signaling pathways or epigenetic
modifiers. A recent investigation into possible regulators of
airway remodeling found that inhibition of aldose reductase
prevents TGFβ1-induced activation of the PI3K/AKT/
GSK3β signaling pathways in a Smad-independent manner
[115]. A separate investigation into the effects of the plant-
derived propolis on TGFβ1-induced signaling pathways
and EMT in alveolar epithelial cells demonstrated that this
compound prevents TGFβ1-induced cellular changes, sup-
pressed activation of Smad2 and AKT signaling pathways
and may be an inhibitor of airway remodeling [116]. The
central role of histone modifications and cyclin dependent
kinases in EMT [20] are also worthy of further exploration.
Summary
A hallmark of early asthma is the presence of epithelial
injury/repair and expansion of subepithelial fibrosis. In the
setting of chronic TGFβ stimulation from innate eosino-
phils and other leukocytes, modulated by ECM, epithelial
cells undergo dramatic cellular transition known as type II
EMT. Accumulating evidence from in vitro, animal and hu-
man studies suggest that chronic and refractory asthma is
associated with type II EMT. EMT induces loss of mucosal
barrier function, acquisition of mesenchymal characteristics
and enhanced motility, and secretion of fibrotic proteins
accounting for the remodeling phenotype of this disease.
Here we review the evidence for EMT in producing defects
in inducible phenotype of the epithelial cells including alter-
ations in signal response characteristics of the innate re-
sponse of the airways. Applications of systems level studies
will be needed to unravel the dynamic and cross-talk signal-
ing mechanisms characteristic of EMT. These exciting
studies suggest that modulation of EMT may have thera-
peutic implications for reversing airway remodeling, restor-
ing glucocorticoid response, and/or the innate immune
defect observed in severe asthma.
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